Showing 1-10 of 23 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Role of oxidative post-translational modifications in generating neoepitopes | Weill Medical College of Cornell University | Laura Santambrogio | Cures | 01-April-2025 to 31-March-2028 | $600,000.00 |
| Co-transplantation of adaptive human endothelium and islets within encapsulated angiogenic hydrogels for durable engraftment | Weill Medical College of Cornell University | Shahin Rafii | Cures | 01-December-2023 to 30-November-2026 | $1,000,000.00 |
| Achieving persistent presentation of self-antigens to reestablish tolerance and prevent autoimmune diabetes | Trustees of Columbia University in the City of New York | Camillo Bechi Genzano | Cures | 01-March-2025 to 29-February-2028 | $256,285.00 |
| Improving pig islet transplant efficacy in a preclinical baboon diabetes model with induced immune tolerance to the xenografts | Trustees of Columbia University in the City of New York | Megan Sykes | Cures | 01-June-2024 to 31-May-2026 | $599,999.94 |
| In vivo analysis of human islet graft infiltration and its immunomodulation by antigen-specific therapy | Trustees of Columbia University in the City of New York | Remi Creusot | Cures | 01-August-2022 to 31-July-2025 | $699,997.82 |
| Low level engraftment of modified HSCs for continuous and omnipresent autoantigen exposure as requirements to establish tolerance | Trustees of Columbia University in the City of New York | Remi Creusot | Cures | 01-June-2024 to 31-January-2026 | $188,704.16 |
| Project Equity | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-May-2024 to 30-April-2026 | $245,172.00 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-March-2026 | $1,808,522.70 |
| Engineering hypoimmune cells for Type 1 Diabetes | New York Stem Cell Foundation, Inc. | Daniel Paull | Cures | 01-May-2025 to 30-April-2028 | $1,498,415.83 |
| GPR75, a novel actor in beta cell regeneration | New York Medical College | Ercument Dirice | Cures | 01-April-2022 to 31-March-2026 | $750,000.00 |